文献速递重症综合管理与镇静镇痛心脑血管急症消化、代谢与肾脏急症

基于PI3K/AKT/NF-ΚB信号通路探讨骆驼乳清蛋白对不同菌株所致脓毒症小鼠心肌损伤的保护作用

[Exploring the protective effect of camel whey protein on myocardial damage in mice with sepsis caused by different bacterial strains based on the PI3K/AKT/NF-ΚB signaling pathway].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2026-01-01
一句话结论小鼠实验中,骆驼乳清蛋白200 mg/kg灌胃7天预处理可减轻革兰阳性或阴性菌脓毒症的心肌损伤并改善心功能,机制可能与抑制PI3K/AKT/NF-ΚB通路有关。

该研究将40只雄性C57BL/6小鼠随机分为假手术组、革兰阳性菌脓毒症组、革兰阳性菌+骆驼乳清蛋白预处理组、革兰阴性菌脓毒症组、革兰阴性菌+骆驼乳清蛋白预处理组,每组8只。脓毒症模型通过腹腔注射1 mL金黄色葡萄球菌或大肠杆菌悬液建立,预处理组在造模前以骆驼乳清蛋白200 mg/kg、250 μL灌胃,每日1次,连续7天。造模7天后,与相应脓毒症组相比,骆驼乳清蛋白预处理组LVEF、LVFS升高,LVEDD、LVESD、LVEDV、LVESV降低,血清cTnI、CK-MB、IL-1β、IL-6、TNF-α降低、IL-10升高,心肌病理评分降低,心肌p-PI3K、p-AKT、p-P65表达降低,差异均有统计学意义(均P<0.05)。作者认为骆驼乳清蛋白可抑制促炎因子过度释放、促进抗炎因子上调、减轻心肌炎症反应并改善心功能,机制可能与调控PI3K/AKT/NF-ΚB信号通路有关。

要点

  • 小鼠脓毒症模型造模前以骆驼乳清蛋白200 mg/kg、250 μL灌胃,每日1次、连续7天预处理,可改善革兰阳性菌与革兰阴性菌脓毒症小鼠的心功能。
  • 革兰阳性菌脓毒症中,骆驼乳清蛋白预处理组LVEF 0.582±0.033 vs 革兰阳性菌脓毒症组0.464±0.019,LVFS(29.66±1.92)% vs(22.11±1.67)%,均P<0.05。
  • 革兰阴性菌脓毒症中,骆驼乳清蛋白预处理组LVEF 0.636±0.040 vs 革兰阴性菌脓毒症组0.561±0.027,LVFS(33.13±2.80)% vs(27.69±1.93)%,均P<0.05。
  • 骆驼乳清蛋白预处理降低革兰阳性菌与革兰阴性菌脓毒症小鼠血清cTnI、CK-MB、IL-1β、IL-6、TNF-α,升高IL-10,并降低心肌病理评分(均P<0.05)。
  • 骆驼乳清蛋白预处理降低心肌p-PI3K、p-AKT、p-P65蛋白表达,作者认为其心肌保护机制可能与调控PI3K/AKT/NF-ΚB信号通路有关。

适用人群与场景

  • 雄性C57BL/6小鼠,共40只,随机分为5组、每组8只。
  • 革兰阳性菌脓毒症模型经腹腔注射1 mL金黄色葡萄球菌悬液建立,革兰阴性菌脓毒症模型经腹腔注射1 mL大肠杆菌悬液建立,假手术组腹腔注射等量生理盐水。

处置流程与药物剂量

  • 预处理组在造模前以骆驼乳清蛋白200 mg/kg、250 μL灌胃,每日1次,连续7天;其余组以等量生理盐水灌胃。
  • 造模7天后行超声心动图评估LVEF、LVFS、LVEDD、LVESD、LVEDV、LVESV,以酶联免疫吸附法测血清CK-MB、cTnI及IL-1β、IL-6、IL-10、TNF-α,HE染色观察心肌病理,Western blotting检测心肌PI3K/AKT/NF-ΚB通路相关蛋白。

研究设计与关键结果

  • 研究类型为动物实验,40只雄性C57BL/6小鼠随机分为假手术组、革兰阳性菌脓毒症组、革兰阳性菌+骆驼乳清蛋白预处理组、革兰阴性菌脓毒症组、革兰阴性菌+骆驼乳清蛋白预处理组,每组8只。
  • 与假手术组相比,革兰阳性菌与革兰阴性菌脓毒症组LVEF、LVFS降低,LVEDD、LVESD、LVEDV、LVESV升高,血清CK-MB、cTnI、TNF-α、IL-1β、IL-6、IL-10升高,心肌病理评分升高,心肌p-PI3K、p-AKT、p-P65表达上调(均P<0.05)。
  • 革兰阳性菌脓毒症中,骆驼乳清蛋白预处理组vs革兰阳性菌脓毒症组:LVEF 0.582±0.033 vs 0.464±0.019,LVFS(29.66±1.92)% vs(22.11±1.67)%,LVEDD(mm)2.64±0.13 vs 3.38±0.29,LVESD(mm)1.65±0.09 vs 2.42±0.24,LVEDV(μL)43.67±8.93 vs 70.08±3.31,LVESV(μL)19.73±4.79 vs 36.36±2.89,均P<0.05。
  • 革兰阴性菌脓毒症中,骆驼乳清蛋白预处理组vs革兰阴性菌脓毒症组:LVEF 0.636±0.040 vs 0.561±0.027,LVFS(33.13±2.80)% vs(27.69±1.93)%,LVEDD(mm)2.58±0.19 vs 2.98±0.27,LVESD(mm)1.70±0.12 vs 2.45±0.21,LVEDV(μL)35.40±2.94 vs 47.73±4.86,LVESV(μL)14.16±2.54 vs 21.90±3.49,均P<0.05。
  • 革兰阳性菌脓毒症中,骆驼乳清蛋白预处理组vs革兰阳性菌脓毒症组:cTnI(ng/L)855.37±15.22 vs 1415.93±14.85,CK-MB(μg/L)14.13±1.30 vs 20.63±1.52,IL-1β(ng/L)252.79±18.77 vs 398.89±11.23,IL-6(ng/L)142.93±5.78 vs 205.15±2.74,TNF-α(ng/L)181.33±4.47 vs 271.44±7.43,IL-10(ng/L)248.22±11.71 vs 205.57±13.69,均P<0.05。
  • 革兰阴性菌脓毒症中,骆驼乳清蛋白预处理组vs革兰阴性菌脓毒症组:cTnI(ng/L)727.42±18.55 vs 1089.57±15.11,CK-MB(μg/L)8.75±1.48 vs 17.81±0.88,IL-1β(ng/L)242.09±13.49 vs 363.45±8.78,IL-6(ng/L)104.18±7.16 vs 173.29±5.60,TNF-α(ng/L)134.97±10.49 vs 241.20±6.86,IL-10(ng/L)312.90±8.82 vs 256.52±8.12,均P<0.05。
  • 骆驼乳清蛋白预处理组心肌病理评分低于相应脓毒症组:革兰阳性菌中0.83±0.20 vs 1.71±0.12,革兰阴性菌中0.73±0.08 vs 1.74±0.13,均P<0.05;心肌p-PI3K/β-actin、p-AKT/β-actin、p-P65/β-actin表达均降低(均P<0.05)。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠脓毒症模型)。
  • 作者结论:骆驼乳清蛋白可抑制革兰阳性菌或革兰阴性菌脓毒症小鼠血清促炎细胞因子过度释放、促进抗炎细胞因子上调、减轻心肌炎症反应并改善心功能,机制可能与调控PI3K/AKT/NF-ΚB信号通路有关。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该研究为小鼠实验,骆驼乳清蛋白200 mg/kg灌胃7天预处理的结果尚不能直接转化为脓毒症心肌损伤的临床处置。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the protective effects and mechanisms of camel whey protein (CWP) against myocardial injury in mice with sepsis caused by Gram-positive bacteria or Gram-negative bacteria.

METHODS: Using a random number table, 40 male C57BL/6 mice were divided into the Sham group, Gram-positive bacterial sepsis group (G+ group), CWP-pretreated Gram-positive bacterial sepsis group (G+CWP group), Gram-negative bacterial sepsis group (G- group), CWP-pretreated Gram-negative bacterial sepsis group (G-CWP group), with 8 mice in each group. The Gram-positive bacterial sepsis model and the Gram-negative bacterial sepsis model were established by intraperitoneal injection of 1 mL of Staphylococcus aureus/Escherichia coli suspension, respectively; the Sham group received an equal volume of saline. In the pretreatment groups, CWP (200 mg/kg, 250 μL) was administered via oral gavage once daily for 7 days prior to model induction; the remaining groups received an equal volume of saline via oral gavage. Seven days after modeling, echocardiography was used to assess cardiac function parameters, including left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV). The levels of serum myocardial injury markers [MB isoenzyme of creatine kinase (CK-MB), cardiac troponin I (cTnI)] and inflammatory factors [interleukins (IL-1β, IL-6, IL-10), tumor necrosis factor-α (TNF-α)] were measured by enzyme linked immunosorbent assay (ELISA). Pathological changes in myocardial tissue were observed by hematoxylin-eosin (HE) staining. The expression of proteins associated with the PI3K/AKT/NF-ΚB signaling pathway in myocardial tissue were detected by Western blotting.

RESULTS: Compared with the Sham group, the G+ and G- groups showed decreased cardiac function parameters (LVEF and LVFS) and increased LVEDD, LVESD, LVEDV, and LVESV, as well as elevated serum levels of CK-MB, cTnI, TNF-α, IL-1β, IL-6, and IL-10; myocardial tissue showed widened interfiber spaces, marked interstitial congestion, inflammatory cell infiltration, and increased myocardial injury pathological scores; the expression of phosphorylated PI3K (p-PI3K), phosphorylated AKT (p-AKT), and phosphorylated P65 (p-P65) proteins were upregulated in myocardial tissue (all P<0.05). Compared with the corresponding G+ and G- groups, the G+CWP and G-CWP groups showed improvements in cardiac function, with increased LVEF and LVFS [LVEF: 0.582±0.033 vs. 0.464±0.019, 0.636±0.040 vs. 0.561±0.027; LVFS: (29.66±1.92)% vs. (22.11±1.67)%, (33.13±2.80)% vs. (27.69±1.93)%], while LVEDD, LVESD, LVEDV, and LVESV decreased [LVEDD (mm): 2.64±0.13 vs. 3.38±0.29, 2.58±0.19 vs. 2.98±0.27; LVESD (mm): 1.65±0.09 vs. 2.42±0.24, 1.70±0.12 vs. 2.45±0.21; LVEDV (μL): 43.67±8.93 vs. 70.08±3.31, 35.40±2.94 vs. 47.73±4.86; LVESV (μL): 19.73±4.79 vs. 36.36±2.89, 14.16±2.54 vs. 21.90±3.49]; reduced serum levels of cTnI, CK-MB, IL-1β, IL-6, and TNF-α [cTnI (ng/L): 855.37±15.22 vs. 1 415.93±14.85, 727.42±18.55 vs. 1 089.57±15.11; CK-MB (μg/L): 14.13±1.30 vs. 20.63±1.52, 8.75±1.48 vs. 17.81±0.88; IL-1β (ng/L): 252.79±18.77 vs. 398.89±11.23, 242.09±13.49 vs. 363.45±8.78; IL-6 (ng/L): 142.93±5.78 vs. 205.15±2.74, 104.18±7.16 vs. 173.29±5.60; TNF-α (ng/L): 181.33±4.47 vs. 271.44±7.43, 134.97±10.49 vs. 241.20±6.86], levels of the anti-inflammatory factor IL-10 increased (ng/L: 248.22±11.71 vs. 205.57±13.69, 312.90±8.82 vs. 256.52±8.12); pathological damage to myocardial tissue was reduced, with lower scores (0.83±0.20 vs. 1.71±0.12, 0.73±0.08 vs. 1.74±0.13); the expression of p-PI3K, p-AKT, and p-P65 proteins were all reduced in myocardial tissue [p-PI3K/β-actin: 0.49±0.20 vs. 0.93±0.08, 0.53±0.02 vs. 0.67±0.05; p-AKT/β-actin: 0.75±0.17 vs. 1.10±0.12, 0.73±0.10 vs. 0.92±0.05; p-P65/β-actin: 0.38±0.04 vs. 0.59±0.09, 0.39±0.07 vs. 0.54±0.03], with all differences being statistically significant (all P<0.05).

CONCLUSIONS: CWP can suppress the excessive release of pro-inflammatory cytokines in the serum of mice with sepsis caused by Gram-positive bacteria or Gram-negative bacteria, promote the upregulation of anti-inflammatory cytokines, alleviate inflammatory responses in the myocardial tissue of septic mice, and improve their cardiac function; its mechanism may be related to the regulation of the PI3K/AKT/NF-ΚB signaling pathway.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Jiang B, You W, Xue Q, et al. [Exploring the protective effect of camel whey protein on myocardial damage in mice with sepsis caused by different bacterial strains based on the PI3K/AKT/NF-ΚB signaling pathway]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 42281537. doi:10.3760/cma.j.cn121430-20250904-00473

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。